In the CART19-BE-01 trial (NCT03144583)—one of the first European academic clinical trials of CD19 CAR-T−47 patients with B-cell malignancies were infused with ARI-0001, among them 38 with R/R BCP-ALL (including 11 children) of whom 87% had post-HSCT relapse (28). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.